TY - JOUR T1 - Mapping a Pandemic: SARS-CoV-2 Seropositivity in the United States JF - medRxiv DO - 10.1101/2021.01.27.21250570 SP - 2021.01.27.21250570 AU - Heather Kalish AU - Carleen Klumpp-Thomas AU - Sally Hunsberger AU - Holly Ann Baus AU - Michael P Fay AU - Nalyn Siripong AU - Jing Wang AU - Jennifer Hicks AU - Jennifer Mehalko AU - Jameson Travers AU - Matthew Drew AU - Kyle Pauly AU - Jacquelyn Spathies AU - Tran Ngo AU - Kenneth M. Adusei AU - Maria Karkanitsa AU - Jennifer A Croker AU - Yan Li AU - Barry I. Graubard AU - Lindsay Czajkowski AU - Olivia Belliveau AU - Cheryl Chairez AU - Kelly Snead AU - Peter Frank AU - Anandakumar Shunmugavel AU - Alison Han AU - Luca T. Giurgea AU - Luz Angela Rosas AU - Rachel Bean AU - Rani Athota AU - Adriana Cervantes-Medina AU - Monica Gouzoulis AU - Brittany Heffelfinger AU - Shannon Valenti AU - Rocco Caldararo AU - Michelle M. Kolberg AU - Andrew Kelly AU - Reid Simon AU - Saifullah Shafiq AU - Vanessa Wall AU - Susan Reed AU - Eric W Ford AU - Ravi Lokwani AU - John-Paul Denson AU - Simon Messing AU - Sam G. Michael AU - William Gillette AU - Robert P. Kimberly AU - Steven E. Reis AU - Matthew D. Hall AU - Dominic Esposito AU - Matthew J. Memoli AU - Kaitlyn Sadtler Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/31/2021.01.27.21250570.abstract N2 - Asymptomatic SARS-CoV-2 infection and delayed implementation of diagnostics have led to poorly defined viral prevalence rates. To address this, we analyzed seropositivity in US adults who have not previously been diagnosed with COVID-19. Individuals with characteristics that reflect the US population (n = 11,382) and who had not previously been diagnosed with COVID-19 were selected by quota sampling from 241,424 volunteers (ClinicalTrials.gov NCT04334954). Enrolled participants provided medical, geographic, demographic, and socioeconomic information and 9,028 blood samples. The majority (88.7%) of samples were collected between May 10th and July 31st, 2020. Samples were analyzed via ELISA for anti-Spike and anti-RBD antibodies. Estimation of seroprevalence was performed by using a weighted analysis to reflect the US population. We detected an undiagnosed seropositivity rate of 4.6% (95% CI: 2.6 – 6.5%). There was distinct regional variability, with heightened seropositivity in locations of early outbreaks. Subgroup analysis demonstrated that the highest estimated undiagnosed seropositivity within groups was detected in younger participants (ages 18-45, 5.9%), females (5.5%), Black/African American (14.2%), Hispanic (6.1%), and Urban residents (5.3%), and lower undiagnosed seropositivity in those with chronic diseases. During the first wave of infection over the spring/summer of 2020 an estimate of 4.6% of adults had a prior undiagnosed SARS-CoV-2 infection. These data indicate that there were 4.8 (95% CI: 2.8-6.8) undiagnosed cases for every diagnosed case of COVID-19 during this same time period in the United States, and an estimated 16.8 million undiagnosed cases by mid-July 2020.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04334954Funding StatementThis project has been funded in part with Federal funds from the National Cancer Institute, National Institutes of Health, under contract number HHSN261200800001E, 75N91019D00024, Task Order No. 75N91019F00130, Clinical and Translational Science Awards Program grants UL1TR003096 (UAB) and UL1TR001857 (University of Pittsburgh). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. Disclaimer: The NIH, its officers, and employees do not recommend or endorse any company, product, or service.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study (ClinicalTrials.gov NCT04334954) was approved by the National Institutes of Health Institutional Review Board and conducted in accordance with the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines. All participants provided verbal informed consent prior to enrollment.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request to corresponding authors on a case-by-case basis as the clinical study is still ongoing. ER -